Literature DB >> 27481054

Longevity of Genotype-Specific Immune Responses to Plasmodium falciparum Merozoite Surface Protein 1 in Kenyan Children from Regions of Different Malaria Transmission Intensity.

Natalie M Bowman1, Jonathan J Juliano2, Cynthia J Snider3, Oksana Kharabora1, Steven R Meshnick3, John Vulule4, Chandy C John5, Ann M Moormann6.   

Abstract

Naturally acquired immunity to Plasmodium falciparum presents a changing landscape as malaria control programs and vaccine initiatives are implemented. Determining which immunologic indicators remain surrogates of past infection, as opposed to mediators of protection, led us to compare stability of immune responses across regions with divergent malaria transmission intensities. A repeat cross-sectional study of Kenyan children from a malaria-holoendemic area and an epidemic-prone area was used to examine longitudinal antibody and interferon-gamma (IFN-γ) responses to the 3D7 and FVO variants of merozoite surface protein 1 (MSP1). Antibodies to MSP1 were common in both study populations and did not significantly wane over a 21-month time period. IFN-γ responses were less frequent and rapidly disappeared in children after a prolonged period of no malaria transmission. Antibody and IFN-γ responses rarely correlated with each other; however, MSP1-specific IFN-γ response correlated with lack of concurrent P. falciparum parasitemia of the same genotype, though only statistically significantly in the malaria-holoendemic region (odds ratio = 0.31, 95% confidence interval = 0.12-0.84). This study affirms that antimalarial antibodies are informative for evaluation of history of malaria exposure within individuals, whereas cell-mediated immunity, though short lived under natural exposure conditions, might provide an assessment of recent infection and protection from parasitemia. © The American Society of Tropical Medicine and Hygiene.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27481054      PMCID: PMC5014263          DOI: 10.4269/ajtmh.15-0710

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  46 in total

1.  Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection.

Authors:  Katie L Flanagan; Tabitha Mwangi; Magdalena Plebanski; Kennedy Odhiambo; Amanda Ross; Eric Sheu; Moses Kortok; Brett Lowe; Kevin Marsh; Adrian V S Hill
Journal:  Am J Trop Med Hyg       Date:  2003-04       Impact factor: 2.345

2.  Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children.

Authors:  Ann M Moormann; Kiprotich Chelimo; Odada P Sumba; Mary L Lutzke; Robert Ploutz-Snyder; Duane Newton; James Kazura; Rosemary Rochford
Journal:  J Infect Dis       Date:  2005-03-09       Impact factor: 5.226

3.  IFNγ Responses to Pre-erythrocytic and Blood-stage Malaria Antigens Exhibit Differential Associations With Past Exposure and Subsequent Protection.

Authors:  Prasanna Jagannathan; Felistas Nankya; Cristina Stoyanov; Ijeoma Eccles-James; Esther Sikyomu; Kate Naluwu; Samuel Wamala; Mayimuna Nalubega; Jessica Briggs; Katherine Bowen; Victor Bigira; James Kapisi; Moses R Kamya; Grant Dorsey; Margaret E Feeney
Journal:  J Infect Dis       Date:  2014-12-17       Impact factor: 5.226

4.  Serological evidence for long-term Epstein-Barr virus reactivation in children living in a holoendemic malaria region of Kenya.

Authors:  Erwan Piriou; Rhonda Kimmel; Kiprotich Chelimo; Jaap M Middeldorp; Peter Sumba Odada; Robert Ploutz-Snyder; Ann M Moormann; Rosemary Rochford
Journal:  J Med Virol       Date:  2009-06       Impact factor: 2.327

5.  Primary structure of the precursor to the three major surface antigens of Plasmodium falciparum merozoites.

Authors:  A A Holder; M J Lockyer; K G Odink; J S Sandhu; V Riveros-Moreno; S C Nicholls; Y Hillman; L S Davey; M L Tizard; R T Schwarz
Journal:  Nature       Date:  1985 Sep 19-25       Impact factor: 49.962

6.  Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains.

Authors:  M J Blackman; I T Ling; S C Nicholls; A A Holder
Journal:  Mol Biochem Parasitol       Date:  1991-11       Impact factor: 1.759

7.  Recurrent Plasmodium falciparum malaria infections in Kenyan children diminish T-cell immunity to Epstein Barr virus lytic but not latent antigens.

Authors:  Cynthia J Snider; Stephen R Cole; Kiprotich Chelimo; Peter Odada Sumba; Pia D M Macdonald; Chandy C John; Steven R Meshnick; Ann M Moormann
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

Review 8.  How might infant and paediatric immune responses influence malaria vaccine efficacy?

Authors:  A M Moormann
Journal:  Parasite Immunol       Date:  2009-09       Impact factor: 2.280

9.  The Plasmodium falciparum merozoite surface protein-1 19 KD antibody response in the Peruvian Amazon predominantly targets the non-allele specific, shared sites of this antigen.

Authors:  Patrick L Sutton; Eva H Clark; Claudia Silva; OraLee H Branch
Journal:  Malar J       Date:  2010-01-04       Impact factor: 2.979

10.  Seasonal changes in the antibody responses against Plasmodium falciparum merozoite surface antigens in areas of differing malaria endemicity in Indonesia.

Authors:  Supargiyono Supargiyono; Michael T Bretscher; Mahardika A Wijayanti; Inge Sutanto; Dian Nugraheni; Royhan Rozqie; Ayleen A Kosasih; Sulistyawati Sulistyawati; William A Hawley; Neil F Lobo; Jackie Cook; Chris J Drakeley
Journal:  Malar J       Date:  2013-12-09       Impact factor: 2.979

View more
  3 in total

1.  Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial.

Authors:  Antje Blank; Kristin Fürle; Anja Jäschke; Michael Lanzer; Walter E Haefeli; Hermann Bujard; Gerd Mikus; Monika Lehmann; Johannes Hüsing; Kirsten Heiss; Thomas Giese; Darrick Carter; Ernst Böhnlein
Journal:  NPJ Vaccines       Date:  2020-01-31       Impact factor: 7.344

2.  Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial.

Authors:  Antje Blank; Kristin Fürle; Anja Jäschke; Michael Lanzer; Walter E Haefeli; Hermann Bujard; Gerd Mikus; Monika Lehmann; Johannes Hüsing; Kirsten Heiss; Thomas Giese; Darrick Carter; Ernst Böhnlein
Journal:  NPJ Vaccines       Date:  2020-01-31       Impact factor: 7.344

Review 3.  Naturally Acquired Antibodies against Plasmodium falciparum: Friend or Foe?

Authors:  Muyideen Kolapo Tijani; Allan Lugaajju; Kristina E M Persson
Journal:  Pathogens       Date:  2021-07-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.